RATIONALE: Several studies suggest that patients with asthma who are homozygous for arginine at the 16th position of the beta2-adrenergic receptor may not benefit from short-acting beta-agonists. OBJECTIVES: We investigated whether such genotype-specific effects occur when patients are treated with long-acting beta-agonists and whether such effects are modified by concurrent inhaled corticosteroid (ICS) use. METHODS: We compared salmeterol response in patients with asthma homozygous for arginine at B16 (B16Arg/Arg) with those homozygous for glycine at B16 (B16Gly/Gly) in two separate cohorts. In the first, subjects were randomized to regular therapy with salmeterol while simultaneously discontinuing ICS therapy. In the second, subjects were randomized to regular therapy with salmeterol while continuing concomitant ICS. RESULTS: In both trials, B16Arg/Arg subjects did not benefit compared with B16Gly/Gly subjects after salmeterol was initiated. In the first cohort, compared with placebo, the addition of salmeterol was associated with a 51.4 L/min lower A.M. peak expiratory flow (PEF; p = 0.005) in B16Arg/Arg subjects(salmeterol, n = 12; placebo, n = 5) as compared with B16Gly/Gly subjects (salmeterol, n = 13; placebo, n = 13). In the second cohort, B16Arg/Arg subjects treated with salmeterol and ICS concurrently (n = 8) had a lower A.M. PEF (36.8 L/min difference, p = 0.048) than B16Gly/Gly subjects (n = 22) treated with the same regimen. In addition, B16 Arg/Arg subjects in the second cohort had lower FEV1 (0.42 L, p = 0.003), increased symptom scores (0.2 units, p = 0.034), and increased albuterol rescue use (0.95 puffs/d, p = 0.004) compared with B16Gly/Gly subjects. CONCLUSIONS: Relative to B16Gly/Gly patients with asthma, B16Arg/Arg patients with asthma may have an impaired therapeutic response to salmeterol in either the absence or presence of concurrent ICS use. Investigation of alternate treatment strategies may benefit this group.
RCT Entities:
RATIONALE: Several studies suggest that patients with asthma who are homozygous for arginine at the 16th position of the beta2-adrenergic receptor may not benefit from short-acting beta-agonists. OBJECTIVES: We investigated whether such genotype-specific effects occur when patients are treated with long-acting beta-agonists and whether such effects are modified by concurrent inhaled corticosteroid (ICS) use. METHODS: We compared salmeterol response in patients with asthma homozygous for arginine at B16 (B16Arg/Arg) with those homozygous for glycine at B16 (B16Gly/Gly) in two separate cohorts. In the first, subjects were randomized to regular therapy with salmeterol while simultaneously discontinuing ICS therapy. In the second, subjects were randomized to regular therapy with salmeterol while continuing concomitant ICS. RESULTS: In both trials, B16Arg/Arg subjects did not benefit compared with B16Gly/Gly subjects after salmeterol was initiated. In the first cohort, compared with placebo, the addition of salmeterol was associated with a 51.4 L/min lower A.M. peak expiratory flow (PEF; p = 0.005) in B16Arg/Arg subjects(salmeterol, n = 12; placebo, n = 5) as compared with B16Gly/Gly subjects (salmeterol, n = 13; placebo, n = 13). In the second cohort, B16Arg/Arg subjects treated with salmeterol and ICS concurrently (n = 8) had a lower A.M. PEF (36.8 L/min difference, p = 0.048) than B16Gly/Gly subjects (n = 22) treated with the same regimen. In addition, B16 Arg/Arg subjects in the second cohort had lower FEV1 (0.42 L, p = 0.003), increased symptom scores (0.2 units, p = 0.034), and increased albuterol rescue use (0.95 puffs/d, p = 0.004) compared with B16Gly/Gly subjects. CONCLUSIONS: Relative to B16Gly/Glypatients with asthma, B16Arg/Argpatients with asthma may have an impaired therapeutic response to salmeterol in either the absence or presence of concurrent ICS use. Investigation of alternate treatment strategies may benefit this group.
Authors: C R Newton; L E Heptinstall; C Summers; M Super; M Schwarz; R Anwar; A Graham; J C Smith; A F Markham Journal: Lancet Date: 1989 Dec 23-30 Impact factor: 79.321
Authors: C R Newton; A Graham; L E Heptinstall; S J Powell; C Summers; N Kalsheker; J C Smith; A F Markham Journal: Nucleic Acids Res Date: 1989-04-11 Impact factor: 16.971
Authors: E Israel; J M Drazen; S B Liggett; H A Boushey; R M Cherniack; V M Chinchilli; D M Cooper; J V Fahy; J E Fish; J G Ford; M Kraft; S Kunselman; S C Lazarus; R F Lemanske; R J Martin; D E McLean; S P Peters; E K Silverman; C A Sorkness; S J Szefler; S T Weiss; C N Yandava Journal: Am J Respir Crit Care Med Date: 2000-07 Impact factor: 21.405
Authors: S C Lazarus; H A Boushey; J V Fahy; V M Chinchilli; R F Lemanske; C A Sorkness; M Kraft; J E Fish; S P Peters; T Craig; J M Drazen; J G Ford; E Israel; R J Martin; E A Mauger; S A Nachman; J D Spahn; S J Szefler Journal: JAMA Date: 2001 May 23-30 Impact factor: 56.272
Authors: C M Drysdale; D W McGraw; C B Stack; J C Stephens; R S Judson; K Nandabalan; K Arnold; G Ruano; S B Liggett Journal: Proc Natl Acad Sci U S A Date: 2000-09-12 Impact factor: 11.205
Authors: D Robin Taylor; Michael J Epton; Martin A Kennedy; Andrew D Smith; Steven Iles; Allison L Miller; Matthew D Littlejohn; Jan O Cowan; Tracey Hewitt; Maureen P Swanney; Karen P Brassett; G Peter Herbison Journal: Am J Respir Crit Care Med Date: 2005-06-23 Impact factor: 21.405
Authors: Shweta Choudhry; Ngim Ung; Pedro C Avila; Elad Ziv; Sylvette Nazario; Jesus Casal; Alfonso Torres; Jennifer D Gorman; Keyan Salari; Jose R Rodriguez-Santana; Monica Toscano; Jody Senter Sylvia; MariaElena Alioto; Richard A Castro; Michael Salazar; Ivan Gomez; Joanne K Fagan; Jorge Salas; Suzanne Clark; Craig Lilly; Henry Matallana; Moises Selman; Rocio Chapela; Dean Sheppard; Scott T Weiss; Jean G Ford; Homer A Boushey; Jeffrey M Drazen; William Rodriguez-Cintron; Edwin K Silverman; Esteban González Burchard Journal: Am J Respir Crit Care Med Date: 2004-11-19 Impact factor: 21.405
Authors: M R Sears; D R Taylor; C G Print; D C Lake; Q Q Li; E M Flannery; D M Yates; M K Lucas; G P Herbison Journal: Lancet Date: 1990-12-08 Impact factor: 79.321
Authors: Gregory A Hawkins; Kelan Tantisira; Deborah A Meyers; Elizabeth J Ampleford; Wendy C Moore; Barbara Klanderman; Stephen B Liggett; Stephen P Peters; Scott T Weiss; Eugene R Bleecker Journal: Am J Respir Crit Care Med Date: 2006-08-24 Impact factor: 21.405
Authors: Ashgan Abdallah Alghobashy; Sahar A Elsharawy; Usama M Alkholy; Nermin Abdalmonem; Mohamed Ali Abdou; Maha A A Basset; Heba Fouad Pasha Journal: Pediatr Res Date: 2018-01-03 Impact factor: 3.756
Authors: Victor E Ortega; Gregory A Hawkins; Stephen P Peters; Eugene R Bleecker Journal: Immunol Allergy Clin North Am Date: 2007-11 Impact factor: 3.479